Advanced Search

Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Articles online first > Giornale Italiano di Dermatologia e Venereologia 2015 Oct 27

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEGIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

A Journal on Dermatology and Sexually Transmitted Diseases

Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014

Frequency: Bi-Monthly

ISSN 0392-0488

Online ISSN 1827-1820

 

Giornale Italiano di Dermatologia e Venereologia 2015 Oct 27

Clinical characteristics and systemic therapies administered in a cohort of patients attending for the first time a tertiary psoriasis outpatient clinic

Bonifati C., Graceffa D., Lora V., Maiani E.

Centre for the study and treatment of psoriasis at the Department of Clinical Dermatology, San Gallicano Dermatologic Institute, IRCCS, Rome, Italy

AIM: To describe the clinical characteristics and the systemic therapies given to a cohort of patients attending for the first time our tertiary outpatients psoriasis clinic.
METHODS: Data were extracted from an electronic database where the patients, mostly eligible for systemic therapies, are consecutively recorded. On the basis of skin disease severity the subjects were classified into 3 groups: mild psoriasis (MP; PASI ≤ 5); mild to moderate psoriasis (MMP; PASI >5<10); moderate to severe psoriasis (MSP; PASI > 10).
RESULTS: Of the two hundred and eighty-nine patients studied, 88 (30.4%) presented MP, 91 (31.5%) MMP and 110 (38%) MSP. Of the above cited patients 89 (30.8%) were affected by psoriatic arthritis. Of the 289 patients, 267 (92.3%) were deemed eligible for a systemic treatment. Of the latter, 228 (85.4%) started a systemic treatment as monotherapy. The percentages of the therapies administered were as follows: i) cyclosporine 65 (28.5%); ii) methotrexate 59 (25.8%); iii) etanercept 33 (44%); iv) adalimumab 25 (33.3%); ustekinumab 17 (22.6%), acitretin 29 (12.7%); golimumab 1 (1.3%).
CONCLUSION: Our data show a composite distribution of patients eligible for a systemic therapy and attending for the first time our centre. The traditional drugs were more frequently administered (67.1%) as compared to biological ones (32.9%).

language: English


FULL TEXT  REPRINTS

top of page